Regenerative and experimental therapies
Cooling, CBD, stem cells and exosomes, brain stimulation, light and peptides — what is genuinely evidence-based, what is investigational, and what to be wary of.
Families of children with neurological conditions are increasingly offered 'regenerative' or experimental treatments — from cell therapies and exosomes to brain stimulation and light therapy. A few have a solid evidence base for specific situations; most are still investigational; and some are marketed aggressively, at high cost, outside any regulated trial. This page explains the main approaches honestly, so families can tell them apart.
At a glance
- Evidence-based (specific use)
- Therapeutic hypothermia for newborn HIE; pharmaceutical-grade CBD for certain epilepsies
- Investigational
- Stem cells, exosomes, TMS, photobiomodulation, peptides
- Main risk
- Unregulated 'stem-cell tourism' and unproven cures
- Best approach
- Prefer regulated clinical trials; appraise claims against evidence
Therapeutic hypothermia (head/body cooling)
Controlled cooling of a newborn's brain or body for 72 hours is a genuinely evidence-based, standard treatment — but for one specific situation: moderate-to-severe hypoxic–ischaemic encephalopathy in term newborns, started within about 6 hours of birth. It reduces death and disability. It is a time-critical hospital treatment, not a general 'regenerative' therapy for older children, and cooling has not shown the same benefit in other settings.
Cannabidiol (CBD)
Pharmaceutical-grade cannabidiol is an approved, evidence-based antiseizure medicine for specific drug-resistant epilepsies — Dravet syndrome, Lennox–Gastaut syndrome and tuberous sclerosis–associated seizures — supported by randomized trials. This is quite different from the many over-the-counter 'CBD oils', whose strength, purity and CBD content are not guaranteed and which can interact with other medicines (for example raising levels of clobazam). For epilepsy, the regulated product, prescribed and monitored, is what has been studied.
Pharmaceutical-grade CBD (a regulated medicine) is not the same as the CBD products sold online or in shops — quality, dose and drug interactions differ, and only the regulated product has trial evidence in epilepsy.
Stem-cell and exosome therapies (including intranasal)
Umbilical cord blood and mesenchymal stromal cells are studied in cerebral palsy, autism and other conditions, mainly for their anti-inflammatory and supportive (not tissue-replacing) effects. Trials suggest they are generally safe and may modestly improve some measures, but the best cell type, dose and timing are unsettled and no stem-cell product is approved for these conditions. Stem-cell-derived exosomes (tiny signalling particles), including intranasal delivery, are an earlier, largely preclinical extension of the same idea.
Be very cautious of clinics offering paid 'stem-cell' or exosome cures outside regulated trials. Promising laboratory science does not equal a proven treatment, and unregulated infusions carry real risks.
Transcranial magnetic stimulation (TMS)
TMS uses magnetic pulses to stimulate the brain non-invasively. In children it is being studied for conditions such as autism, hemiparesis in cerebral palsy, depression and migraine. Early studies suggest it is generally safe and tolerable, with possible benefit, but it remains investigational in paediatrics and is best accessed within research settings.
Photobiomodulation (low-level laser) and peptides
Low-level light/laser therapy (photobiomodulation) and various 'peptide' treatments are promoted for a range of neurodevelopmental conditions, but the evidence in children is preliminary and these are not established treatments. They should be approached with the same caution as other experimental options.
How an educational review can help
When a clinic or product promises improvement, an educational review can place the specific claim against the actual evidence, distinguish regulated treatments from unproven ones, and help you ask the right questions before committing time or money. It is educational and does not replace your treating clinician.
Selected sources
- Cochrane and trial evidence for therapeutic hypothermia in neonatal hypoxic–ischaemic encephalopathy.
- Randomized trials of pharmaceutical-grade cannabidiol in Dravet, Lennox–Gastaut and TSC.
- Systematic reviews of cell therapies for cerebral palsy and autism spectrum disorder.
Last reviewed: 2026-05-22
Related conditions
Want a treatment plan explained?
Share your child's records and our specialists will prepare a written educational review.
Start a ReviewZatay Medical provides independent educational reviews only. Our reports are not a diagnosis, treatment, or prescription, and do not replace care from your treating physician.